Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PA-111 PK and Safety Study in Healthy Volunteers
NCT06932705Phase 1Recruiting
- Sponsor
- Addpharma, Inc.
- Start
- Apr 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of PA-111 in mixed dyslipidemia (2 arms), sponsored by Addpharma, Inc. Primary endpoints: Maximum concentration of drug in plasma and Area under the plasma concentration-time curve during dosing interval. Started Apr 2025; status: recruiting.
02
Drugs
PA-111
03
Conditions
mixed dyslipidemia
Beyond the preview
Go deeper on NCT06932705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06932705.